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Summary Cerebellar toxicity is a rare adverse event in patients treated with metronidazole.
Here, we present a patient who developed cerebellar toxicity accompanied by objective
abnormalities on magnetic resonance imaging, and review the literature on this unusual reaction.
Discontinuation of metronidazole almost always results in resolution of symptoms and structural
lesions.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Metronidazole, a 5-nitroimidazole with bactericidal activity
against most anaerobic and facultative anaerobic bacteria
and protozoa, is widely used for the treatment of anaerobic
bacterial and protozoal infections. The drug has few adverse
reactions, most commonly nausea, dry mouth, vomiting, and
diarrhea. Neurologic toxicity is rare and has included per-
ipheral neuropathy, headache, dizziness, syncope, vertigo,
and confusion.1 Cerebellar toxicity is a reported, although
very unusual, manifestation of metronidazole therapy. Here,
we report a case of ataxia and cerebellar lesions following
therapy with metronidazole, which resolved rapidly after
discontinuation of drug therapy, and review the literature
on this unusual adverse event.* Corresponding author. Tel.: +1 732 923 6535; fax: +1 732 923 6536.
E-mail address: atunkel@sbhcs.com (A.R. Tunkel).
1201-9712/$32.00 # 2008 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2008.03.006Case report
A 63-year-old male with a past medical history of schizo-
phrenia presented to an outpatient clinic with purulent
drainage from the mandible. The patient was diagnosed with
a submental abscess and mandibular osteomyelitis. He
underwent surgical drainage of the abscess and mandibular
debridement; cultures grew Streptococcus mitis, Enterococ-
cus faecalis, and Staphylococcus epidermidis. He was dis-
charged on a regimen of metronidazole (500 mg orally every
6 hours) and intravenous vancomycin.
The patient did well, but presented approximately 6
weeks into the course of therapy complaining of progres-
sive unsteadiness of gait and subsequent inability to walk
that began three days earlier. On the day of admission, the
patient reported that he fell while trying to stand after
getting out of bed and was unable to regain his stance.
On neurologic examination, he was alert and oriented toPublished by Elsevier Ltd. All rights reserved.
Figure 1 (a) Axial FLAIRmagnetic resonance image of the head
demonstrates increased signal intensity surrounding the fourth
ventricle, especially involving the medial aspects of the cere-
bellar peduncles and hemispheres. (b) Axial FLAIR magnetic
resonance image of the head demonstrates complete resolution
of the signal abnormality.
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Cranial nerve examination revealed minimal horizontal
nystagmus of 2—3 beats on lateral gaze; there was no
vertical nystagmus. The left pupil was sluggishly reactive
to light. Cerebellar testing revealed that heel-to-
shin maneuvers, finger-to-nose testing, and lateral alter-
nating movements were all normal. The patient’s muscle
strength and bulk tone were normal, and reflexes
were physiologically active and equal except in the ankles
where they were absent bilaterally. His stance was wide-
based; although he could stand with his feet together, he
felt very unsteady and was unable to walk without support.
His sensory exam revealed normal position and thermalsenses, but absent vibration sensation in the toes bilater-
ally. The Romberg sign was negative. A non-contract
computed tomography (CT) scan of the head showed no
evidence of acute hemorrhage, mass effect, or midline
shift.
Upon admission, antimicrobial therapy was discontinued.
Magnetic resonance imaging (MRI) of the head revealed
abnormal T2-hyperintense symmetric signal and nodularity
within the cerebellar parenchyma along the posterior margin
of the fourth ventricle (Figure 1a); no masses, hemorrhage,
or herniation were seen. After discontinuation of metroni-
dazole therapy, the patient began to regain ambulatory
function. He was able to walk with the support of a walker
in two days and was ambulating without support in four
days. The patient was seen in follow-up six weeks later
and he noted no recurrence of symptoms, although there
was persistence of absent vibration sense in the toes bilat-
erally. Repeat MRI of the head revealed complete resolution
of the hyperintense signals in the posterior cerebellum
(Figure 1b).Discussion
Cerebellar toxicity is a rare adverse event in patients
treated with metronidazole, with ten cases previously
reported in the literature; we have summarized these
along with our case in Table 1.2—10 The age range was
17—74 years, with most patients presenting with symptoms
of ataxia and dysarthria; our patient presented with iso-
lated ataxia and no speech impairment. Cerebellar toxicity
was related to high cumulative doses of metronidazole
(range of 25 to 1080 grams). Nine patients had objective
findings on MRI. Despite some variability in clinical and
diagnostic features in these reports, all patients had
ataxia. Cerebellar lesions were described on neuroimaging
studies in all cases except for one patient who had a
normal CT; however, MRI was not performed in this. Fol-
lowing discontinuation of metronidazole therapy, clinical
improvement was noted in all patients in whom it was
reported (generally within 3—7 days), and MRI revealed
resolution of the cerebellar abnormalities in eight patients
who had follow-up studies.
The mechanism by which metronidazole causes cere-
bellar ataxia and reversible MRI findings is unclear. Axonal
swelling has been suggested as one possible mechanism,3
likely a result of localized vasogenic edema, as opposed
to ischemia or demyelination. High doses of metronidazole
in rats have also been shown to induce lesions in the
cerebellum;11 these alterations were qualitatively and
topographically comparable to central nervous system
lesions induced by thiamine deficiency in rats and in
Wernicke’s encephalopathy in humans. Studies in dogs
have found Purkinje cell lesions after prolonged metroni-
dazole administration,12 and other studies in mice have
revealed carbon-labeled metronidazole detected in the
cerebellum.13
In summary, cerebellar toxicity should be considered in
any patient who presents with ataxia and/or dysarthria
and is receiving prolonged therapy with metronidazole.
MRI should be performed for definitive diagnosis and metro-
nidazole should be immediately discontinued. Further stu-
Table 1 Clinical presentation, diagnosis, and outcome of patients with metronidazole cerebellar toxicity
Patient
number
[Ref.]
Patient age, sex,
and symptoms
Total
metronidazole
dose
Neuroimaging
findings
Clinical course after
discontinuation of
therapy
Follow-up
neuroimaging
1 [2] 45-year-old female
with ataxia,
dysarthria, and
paresthesias
84 g CT — normal Ataxia improved on
day 6; paresthesias
resolved at 4 months
Not done
2 [3] 45-year-old female
with ataxia,
confusion, dysarthria,
and painful
peripheral neuropathy
35 g CT — negative Ambulation on day 3;
discharge on day 7;
paresthesias persisted
at >6 weeks
MRI at 6 weeks
showed complete
resolution
MRI — symmetric
T2-weighted
increased signal
in cerebellar nuclei,
genu and splenium
of the corpus
callosum and frontal
and parietal cortical
white matter
3 [4] 34-year-old male with
paresthesias, ataxia,
dysarthria, and
disorientation
66 g MRI — increased
signal intensity in
inferior basal ganglia
lateral to
hypothalamus and
below, behind and
lateral to 4th
ventricle
Cerebellar and speech
symptoms improved
on day 2; residual
paresthesias at 2
weeks
Not done
4 and 5 [5] 62-year-old male with
ataxia and dysarthria
60 g MRI — symmetric
increased
T2-weighted signal
in the dentate,
obtained via FLAIR
images
Ataxia and dysarthria
resolved within 5 weeks
MRI at 5 weeks
showed complete
resolution
74-year-old male with
ataxia and dysarthria
42 g MRI — symmetric
increased T2-weighted
signal in the dentate;
obtained via FLAIR
images
Improvement in ataxia
and dysarthria over
2 weeks
MRI at 2 weeks
showed complete
resolution
6 [6] 17-year-old male with
ataxia, visual
disturbance, tremor,
gait imbalance, and
peripheral neuropathy
500 mg 3 times
daily (total dose
and duration
not specified)
MRI — symmetric foci
of hyperintense signal
on T2-weighted and
FLAIR images in the
red nuclei, substantia
nigra, and splenium
of the corpus callosum
Gait imbalance and
peripheral neuropathy
resolved, visual acuity
improved at 3 months
MRI at 1 year
revealed complete
resolution
7 [7] 50-year-old male with
ataxia, distal sensory
neuropathy, proximal
motor neuropathy,
dizziness, diplopia,
disorientation, and
dysarthria
200 g CT — bilateral
hypodense areas in the
cerebellum
Ataxia and speech
abnormality resolved
at 4 days; neuropathic
symptoms did not
improve
Not done
8 [8] 74-year-old female with
ataxia, dysarthria,
dysphagia, and sensory
neuropathy
180 g MRI — increased signal
intensity in subcortical
white matter, anterior
commissure, splenium,
midbrain, basal ganglia,
and cerebellar white
matter; increased
signal intensity in the
inferior olivary nuclei
Complete resolution
of symptoms at
4 months
MRI at 4 months
showed
near-complete
resolution; inferior
olivary lesions
became
hypertrophied
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Table 1 (Continued )
Patient
number
[Ref.]
Patient age, sex,
and symptoms
Total
metronidazole
dose
Neuroimaging
findings
Clinical course after
discontinuation of
therapy
Follow-up
neuroimaging
9 [9] 54-year-old female with
ataxia and dysarthria
66 g MRI — increased signal
intensity symmetrically
in dentate nuclei seen
on T2-weighted and
FLAIR images
Dysarthria and ataxia
improved on day 3;
complete resolution
on day 7
MRI showed
improvement at
day 10; complete
resolution at
3 months
10 [10] 20-year-old male with
painful distal
paresthesias,
dysarthria, and impaired
coordination of both
hands
1080 g MRI — non-enhancing
T2-weighted increased
signal intensity lesions
in splenium and genu,
and truncus of corpus
callosum
Ataxia improved
after 3—4 weeks;
paresthesias
improved after
3 months; complete
resolution of all
symptoms at 14
months
MRI at 2 and
8 months
showed
gradual
resolution
11 [current
case]
63-year-old with ataxia
and paresthesias
80 g MRI — hyperintense
T2-weighted signal
along posterior margin
of fourth ventricle in
cerebellar parenchyma
Ataxia resolved at
4 days; paresthesias
improved at 6 weeks,
but did not resolve
MRI at 6 weeks
showed complete
resolution of
the lesions
CT, computed tomography; MRI, magnetic resonance imaging.
e114 K. Patel et al.dies are needed to define the pathogenesis of this unusual
event.
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